AL AMYLOIDOSIS

This study is testing whether adding an investigational drug called CAEL-101 to standard treatment helps people with advanced AL amyloidosis live longer and spend less time in the hospital for heart problems. CAEL-101 is designed to help clear harmful protein deposits that build …

This study is testing if adding an investigational drug called CAEL-101 to standard treatment helps people with a severe stage of AL amyloidosis. AL amyloidosis is a disease where abnormal proteins build up and damage organs, especially the heart. The main goal is to see if the c…

This study is testing whether a maintenance therapy with the drug Ixazomib can help control AL amyloidosis and prevent it from coming back after patients have already responded to their first treatment. It involves 17 adults who have achieved at least a partial response to their …

This early-stage study is testing a new, cautious treatment strategy for patients with high-risk AL amyloidosis, a serious disease where abnormal proteins damage organs. Doctors are slowly adding different drugs, starting with isatuximab, to find the most effective combination pa…

This study is testing whether adding a drug called pomalidomide to two other medications (daratumumab and dexamethasone) works better for people with AL amyloidosis that has come back or stopped responding to prior treatment. It is for patients who have already received daratumum…

This study is testing if a drug called siltuximab can reduce the severe fatigue, pain, and nausea that often follow a stem cell transplant. It focuses on patients aged 60-75 with multiple myeloma or AL amyloidosis. The goal is to block a specific protein linked to inflammation, a…